Ovarian Cancer Clinical Trial

A Study of Intra-operative Imaging in Women With Ovarian Cancer

Summary

The purpose of this study is to find out whether using the PINPOINT imaging system intra-operatively can reduce the risk of anastomotic leaks and other complications after surgery for ovarian cancer, compared with standard intra-operative assessments alone. The PINPOINT endoscopic fluorescence imaging system uses a special camera and a fluorescent (glowing) dye that can evaluate the blood flow of the bowel in real-time. If there is an area that appears concerning, the surgeon can correct the problem during the procedure.

View Eligibility Criteria

Eligibility Criteria

Participant Inclusion Criteria

Part 1 (pre-operative):

Diagnosed with primary or recurrent ovarian, fallopian tube, or primary peritoneal cancer
Scheduled to undergo debulking or cytoreductive surgery
Suspected need for a low anterior rectosigmoid resection at the time of a debulking procedure
Enrolled and consented before the operation

Part 2 (intra-operative):

Completed rectosigmoid resection
Surgeon plans to perform colorectal anastomosis

Participant Exclusion Criteria

Part 1 (pre-operative):

Documented history of allergic reaction to ICG
Not approached for study enrollment before undergoing an unexpected low anterior rectosigmoid resection

Part 2 (intra-operative):

Did not undergo rectosigmoid resection intraoperatively
Surgical procedure with rectosigmoid resection for any other type of gynecologic malignancy
Patient requires permanent colostomy

Study is for people with:

Ovarian Cancer

Phase:

Phase 3

Estimated Enrollment:

310

Study ID:

NCT04878094

Recruitment Status:

Recruiting

Sponsor:

Memorial Sloan Kettering Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 8 Locations for this study

See Locations Near You

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge New Jersey, 07920, United States More Info
Mario Leitao, MD
Contact
212-639-3987
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown New Jersey, 07748, United States More Info
Mario Leitao, MD
Contact
212-639-3987
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale New Jersey, 07645, United States More Info
Mario Leitao, MD
Contact
212-639-3987
Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)
Commack New York, 11725, United States More Info
Mario Leitao, MD
Contact
212-639-3987
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison New York, 10604, United States More Info
Mario Leitao, MD
Contact
212-639-3987
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York New York, 10065, United States More Info
Mario Leitao, MD
Contact
212-639-3987
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale New York, 11553, United States More Info
Mario Leitao, MD
Contact
212-639-3987
Jefferson Abington Hospital
Willow Grove Pennsylvania, 19090, United States More Info
Leah Moukarzel, MD
Contact
215-481-4000

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 3

Estimated Enrollment:

310

Study ID:

NCT04878094

Recruitment Status:

Recruiting

Sponsor:


Memorial Sloan Kettering Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.